Navigation Links
EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD

OAK BROOK, Ill., Nov. 5 /PRNewswire/ -- EPI-Q, Inc., a consulting firm providing outcomes research and health economics services to the global biopharmaceutical and healthcare industries, announces the addition of Anthony J. Vita, MD, MPH and Peter Herout, PharmD to their team of clinical professionals. The specialized background of these two practitioners will augment the capabilities EPI-Q is able to offer directly to those clients seeking to enhance the clinical outcomes and cost-effectiveness of patient care.

Both Dr. Herout and Dr. Vita will be responsible for providing clinical support and managing projects within their fields of clinical expertise. "Peter has significant expertise in critical care and cardiology adding to our ability to provide services to hospitals and managed care in both of these important areas. Anthony has clinical skills in mental health, a therapeutic category in which EPI-Q's business is rapidly expanding and his public health training provides additional depth to our methods group," stated EPI-Q President, Mark Jewell.

Dr. Herout has over 8 years experience as a clinical pharmacist. He has spent the majority of his professional career caring for a variety of critically ill patient populations. His most recent practice and research interests have included severe trauma, cardiothoracic surgery, sepsis, glycemic control, infectious diseases, renal replacement therapy, and nutrition support. Before joining EPI-Q, Dr. Herout spent 4 years with Advocate Christ Medical Center in Oak Lawn, Illinois. His contributions to the medical literature have included articles published in Critical Care Medicine and the American Journal of Health-System Pharmacy. He received his PharmD degree from the University of Illinois at Chicago, and completed one-year ASHP-accredited residencies in Pharmacy Practice and Critical Care.

Prior to joining EPI-Q, Dr. Vita worked as a resident physician at the University of Chicago, Department of Psychiatry for 3 years. He has also practiced in a variety of hospital settings including ICU, CCU, general medicine, general pediatrics, pediatric ICU, obstetrics, and neurology. Among the journals publishing Dr. Vita's works are The New England Journal of Medicine, The Journal of Pharmacology and Experimental Therapeutics, and The American Journal of Physiology. Dr. Vita received his Doctor of Medicine degree from Stanford University and Master of Public Health degree from Harvard University.

EPI-Q, Inc. ( provides life sciences companies and healthcare providers and payer organizations with evidence-based solutions that elucidate the value of medical technology and improve health outcomes and cost-effectiveness. EPI-Q's professionals have extensive expertise in medicine, pharmacy, epidemiology, biostatistics, economics, business and healthcare administration. In addition, many of these experts maintain academic affiliations, publish and present frequently on issues pertaining to quality improvement and outcomes management.


Mark Jewell, PhD Andrew M. Baker

President Vice President - Business Development

EPI-Q, Inc. EPI-Q, Inc.

Tel: 630.570.5505 Tel: 914.358.3264

Fax: 630.570.5506 Fax: 914.358.3265

Email: Email:

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):